

ZyCoV-D® as a two-dose vaccine receives EUA from DCGI

- *The two-dose regimen has been approved in the age group of 12 years and above.*
- *With this approval, the vaccine will now be administered on Day 0 and Day 28.*

Ahmedabad, India, 26 April, 2022

Zydus Lifesciences Ltd., a discovery driven global lifesciences company announced that its novel COVID-19 vaccine, ZyCoV-D has received Emergency Use Authorisation (EUA) from the Drug Controller General of India (DCGI) as a two dose vaccine. With this approval, the vaccine will now be administered on day 0 and day 28. Earlier, the vaccine was approved in a three dose regimen to be administered on day 0, day 28 and day 56.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences said, “The approval of a two-dose regimen for ZyCoV-D is a welcome development. This will increase the compliance for the vaccine and reduce the overall time required for vaccination to improve immunity against the virus. It will also help in administering the vaccine in a larger population in a shorter time which is always desirable in the midst of a pandemic.” The two dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age.

Earlier, the safety and efficacy analysis data from Phase III clinical trial of its Plasmid DNA COVID-19 vaccine ZyCoV-D (three dose regimen) has been peer reviewed and published in The Lancet, a reputed and well known medical journal. The results of the Phase I part of the Phase I/II clinical trial (three dose regimen) has also been published in the EClinical Medicine Journal of The Lancet.

About Zydus

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com.



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878